Tuberculosis (TB) still represents a major public health issue in spite of the significant impact
of the efforts made by the World Health Organization (WHO) and partners to improve its …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

The World Health Organization (WHO) estimated that 490 000 cases of multidrug-resistant
(MDR) tuberculosis (TB)(defined as TB caused by Mycobacterium tuberculosis strains …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

The World Health Organization (WHO) recommends that countries implement
pharmacovigilance and collect information on active drug safety monitoring (aDSM) and …

Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …

The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis
(TB) remains a challenge for clinicians for several reasons, including the large number of …

Abstract The World Health Organization (WHO) recommends countries introduce new anti-
TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to …

BACKGROUND: Evidence on the impact of tuberculosis (TB) treatment on lung function is
scarce. The aim of this study was to evaluate post-treatment sequelae in drug-susceptible …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …